Gilead Reports a $320 Million RCUS Buy, Raises Its Stake to 40%

Steve Strazza
January 31, 2024

From the Desk of Steve Strazza and Alfonso Depablos

The largest insider buy on today’s list comes in a series of Form 4 filings by Gilead Sciences.

The American biopharmaceutical company revealed a purchase of roughly $320 million in Arcus Biosciences Inc $RCUS, increasing its ownership stake to 40%.

Article Sales Message

Know the trading behavior of …

  • Senators
  • House Of Representatives
  • C-Suite Executives
  • Hedge Fund Managers
  • Other Big-Power Players

Our experienced team of analysts work through the Form 4, 13D and 13G filings to provide you a list of the best trade ideas.

You need to have a subscription to access this content in full.

Log in or subscribe
Filed Under: